BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 33910041)

  • 1. Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient Administration.
    Alexander M; Culos K; Roddy J; Shaw JR; Bachmeier C; Shigle TL; Mahmoudjafari Z
    Transplant Cell Ther; 2021 Jul; 27(7):558-570. PubMed ID: 33910041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
    Oluwole OO; Dholaria B; Knight TE; Jain T; Locke FL; Ramsdell L; Nikiforow S; Hashmi H; Mooney K; Bhaskar ST; Morris K; Gatwood K; Baer B; Anderson LD; Hamadani M
    Transplant Cell Ther; 2024 Feb; 30(2):131-142. PubMed ID: 37951502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies: A Practical Review.
    Strati P; Gregory T; Majhail NS; Jain N
    JCO Oncol Pract; 2023 Sep; 19(9):706-713. PubMed ID: 37406255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology and Predictors of 30-Day Readmission in CAR-T Cell Therapy Recipients.
    Sharma A; Singh V; Deol A
    Transplant Cell Ther; 2023 Feb; 29(2):108.e1-108.e7. PubMed ID: 36371048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma.
    Lyman GH; Nguyen A; Snyder S; Gitlin M; Chung KC
    JAMA Netw Open; 2020 Apr; 3(4):e202072. PubMed ID: 32250433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities.
    Gutierrez C; Brown ART; Herr MM; Kadri SS; Hill B; Rajendram P; Duggal A; Turtle CJ; Patel K; Lin Y; May HP; Gallo de Moraes A; Maus MV; Frigault MJ; Brudno JN; Athale J; Shah NN; Kochenderfer JN; Dharshan A; Beitinjaneh A; Arias AS; McEvoy C; Mead E; Stephens RS; Nates JL; Neelapu SS; Pastores SM
    J Crit Care; 2020 Aug; 58():58-64. PubMed ID: 32361219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of chimeric antigen receptor T-cells in lymphoma.
    Anderson JK; Mehta A
    Expert Rev Hematol; 2019 Jul; 12(7):551-561. PubMed ID: 31177852
    [No Abstract]   [Full Text] [Related]  

  • 8. Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities.
    Spanjaart AM; Pennings ERA; Kos M; Mutsaers PGNJ; Lugtenburg PJ; van Meerten T; van Doesum JA; Minnema MC; Jak M; van Dorp S; Vermaat JSP; van der Poel MWM; van Oijen MGH; Kuipers MT; Nijhof IS; Kersten MJ
    JCO Oncol Pract; 2023 Mar; 19(3):e407-e416. PubMed ID: 36508702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicities associated with adoptive cellular therapies.
    Hansen DK; Dam M; Faramand RG
    Best Pract Res Clin Haematol; 2021 Sep; 34(3):101287. PubMed ID: 34625233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy.
    Dabas P; Danda A
    Med Oncol; 2023 Aug; 40(9):275. PubMed ID: 37608202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access.
    Ahmed N; Shahzad M; Shippey E; Bansal R; Mushtaq MU; Mahmoudjafari Z; Faisal MS; Hoffmann M; Abdallah AO; Divine C; Hamadani M; McGuirk J; Shune L
    Transplant Cell Ther; 2022 Jul; 28(7):358-364. PubMed ID: 35429662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
    Brudno JN; Kochenderfer JN
    Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigen receptor T-cell therapy: Prospective observational study of unplanned emergency department presentations.
    Bak GG; Micklethwaite K; Maddock K; Coggins A
    Emerg Med Australas; 2023 Dec; 35(6):1034-1037. PubMed ID: 37669879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ophthalmic Implications of Chimeric Antigen Receptor T-Cell Therapy.
    Chodnicki KD; Prasad S
    Semin Ophthalmol; 2021 May; 36(4):329-334. PubMed ID: 33689570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next-Generation Implementation of Chimeric Antigen Receptor T-Cell Therapy Using Digital Health.
    Banerjee R; Shah N; Dicker AP
    JCO Clin Cancer Inform; 2021 Jun; 5():668-678. PubMed ID: 34110929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric Antigen Receptor T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: Current Landscape in 2021.
    Gauthier J; Turtle CJ
    Cancer J; 2021 Mar-Apr 01; 27(2):98-106. PubMed ID: 33750068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies.
    Hu KJ; Yin ETS; Hu YX; Huang H
    Curr Med Sci; 2021 Jun; 41(3):420-430. PubMed ID: 34218353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group Survey on Chimeric Antigen Receptor T Cell Therapy Administrative, Logistic, and Toxicity Management Practices in the United States.
    Mahmoudjafari Z; Hawks KG; Hsieh AA; Plesca D; Gatwood KS; Culos KA
    Biol Blood Marrow Transplant; 2019 Jan; 25(1):26-33. PubMed ID: 30266675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outpatient CAR T-Cell Therapy as Standard of Care: Current Perspectives and Considerations.
    Gatwood K; Mahmoudjafari Z; Baer B; Pak S; Lee B; Kim H; Abernathy K; Dholaria B; Oluwole O
    Clin Hematol Int; 2024; 6(2):11-20. PubMed ID: 38817307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secretory co-factors in next-generation cellular therapies for cancer.
    Okuma A; Ishida Y; Kawara T; Hisada S; Araki S
    Front Immunol; 2022; 13():907022. PubMed ID: 36059449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.